Pharmacology, Toxicology and Pharmaceutical Science
Pembrolizumab
96%
Trastuzumab
96%
Placebo
85%
Metastatic Breast Cancer
72%
Neoplasm
68%
Trilaciclib
64%
Small Cell Lung Cancer
64%
Pertuzumab
64%
Docetaxel
64%
Overall Survival
43%
Progression Free Survival
41%
Epidermal Growth Factor Receptor
40%
Non Small Cell Lung Cancer
36%
Lung Adenocarcinoma
32%
Programmed Death 1 Ligand 1
32%
Erlotinib
32%
Vinorelbine
32%
Afatinib
32%
Phase II Trials
32%
Atezolizumab
32%
Pharmacokinetics
32%
Drug-Drug Interaction
32%
Phase IV
32%
Randomized Clinical Trial
32%
Albumin
32%
Etoposide
18%
Neutropenia
15%
Monotherapy
15%
Glycogen Synthase Kinase
12%
Alprenolol
8%
Serum Albumin
8%
Mortality Rate
8%
Zeneca
8%
Febrile Neutropenia
8%
Pharmacokinetic Parameter
8%
Bone Marrow Suppression
7%
Carboplatin
6%
Survival Rate
6%
Pemetrexed
6%
Diarrhea
6%
Programmed Cell Death
5%
Medicine and Dentistry
Neoplasm
100%
Pembrolizumab
96%
Placebo
84%
Non Small Cell Lung Cancer
68%
Small Cell Lung Cancer
64%
Trilaciclib
64%
Programmed Death 1 Ligand 1
64%
Epidermal Growth Factor Receptor
44%
Overall Survival
38%
Cancer of Unknown Primary Origin
32%
Positron Emission Tomography
32%
Lung Adenocarcinoma
32%
Pertuzumab
32%
Phase II Trials
32%
Docetaxel
32%
Trastuzumab
32%
Atezolizumab
32%
Metastatic Breast Cancer
32%
Albumin
32%
Progression Free Survival
30%
Etoposide
18%
Monotherapy
17%
Hematopoietic Cell
15%
Neutropenia
13%
Intention-to-Treat Analysis
11%
Prospective Study
8%
Serum Albumin
8%
Doctor of Philosophy
8%
Alprenolol
8%
Mortality Rate
8%
Erythrocyte Transfusion
8%
Cumulative Incidence
8%
Pooled Analysis
8%
Drug Dose Reduction
8%
Hazard Ratio
7%
Bone Marrow Suppression
7%
Carboplatin
6%
Survival Rate
6%
Pemetrexed
6%
